Polen Focus Growth Sells Stake in Boston Scientific Due to Competition Concerns
Polen Focus Growth Strategy sold its stake in Boston Scientific (BSX) in Q1 2026 due to rising competition concerns. The strategy underperformed the market, declining 17.16% compared to the S&P 500's -4.33%. Boston Scientific's stock has experienced significant losses, with a 43.18% drop over the past 52 weeks.
Topics: competition concerns investment strategy portfolio changes stock sales